[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2012001284A - Tableta. - Google Patents

Tableta.

Info

Publication number
MX2012001284A
MX2012001284A MX2012001284A MX2012001284A MX2012001284A MX 2012001284 A MX2012001284 A MX 2012001284A MX 2012001284 A MX2012001284 A MX 2012001284A MX 2012001284 A MX2012001284 A MX 2012001284A MX 2012001284 A MX2012001284 A MX 2012001284A
Authority
MX
Mexico
Prior art keywords
tablet
compound
methyl
salt
disclosed
Prior art date
Application number
MX2012001284A
Other languages
English (en)
Inventor
Yusuke Murakawa
Takayuki Okabe
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012001284(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2012001284A publication Critical patent/MX2012001284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe una tableta con dosis de alto nivel, que contiene 2-[[6-[(3R)-3-amino-1-piperidinil]-3,4-dihidro-3-metil- 2,4-dioxo-1 (2H)-pirimidinil]metil]-4-fluorobenzonitrilo (compuesto (A)) o una sal del mismo en la forma de un ingrediente farmacéuticamente activo. Se describe de manera específica una tableta que contiene el compuesto (A) o una sal del mismo, y un fluidizador, con el contenido del compuesto (A) siendo del 35 al 50% en peso.
MX2012001284A 2009-07-28 2010-07-27 Tableta. MX2012001284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009175695 2009-07-28
PCT/JP2010/062568 WO2011013639A1 (ja) 2009-07-28 2010-07-27 錠剤

Publications (1)

Publication Number Publication Date
MX2012001284A true MX2012001284A (es) 2012-03-26

Family

ID=43529294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001284A MX2012001284A (es) 2009-07-28 2010-07-27 Tableta.

Country Status (23)

Country Link
US (1) US20120129878A1 (es)
EP (1) EP2460523B1 (es)
JP (1) JP5732394B2 (es)
KR (1) KR20120039046A (es)
CN (1) CN102548556A (es)
AU (1) AU2010279171A1 (es)
BR (1) BR112012001959A2 (es)
CA (1) CA2769177A1 (es)
CL (1) CL2012000182A1 (es)
CO (1) CO6612226A2 (es)
CR (1) CR20120061A (es)
EA (1) EA201270204A1 (es)
EC (1) ECSP12011699A (es)
IL (1) IL217560A0 (es)
IN (1) IN2012DN00954A (es)
MA (1) MA33539B1 (es)
MX (1) MX2012001284A (es)
PE (1) PE20120919A1 (es)
SG (1) SG178062A1 (es)
TN (1) TN2012000031A1 (es)
TW (1) TW201106991A (es)
WO (1) WO2011013639A1 (es)
ZA (1) ZA201200761B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
TWI580444B (zh) 2012-06-05 2017-05-01 武田藥品工業股份有限公司 固態製劑
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂
CN103877054B (zh) * 2012-12-21 2016-05-25 北大方正集团有限公司 一种苯甲酸阿格列汀片剂及其制备方法
CN105078974A (zh) * 2014-05-23 2015-11-25 深圳信立泰药业股份有限公司 一种阿利沙坦酯固体分散体及药物组合物
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
CN105596341B (zh) * 2016-03-14 2018-08-10 石家庄四药有限公司 一种琥珀酸曲格列汀固体制剂及制备方法
SG11201809835UA (en) 2016-05-10 2018-12-28 Nippon Zoki Pharmaceutical Co Method for manufacturing acetaminophen preparation
CN114122219A (zh) * 2020-08-28 2022-03-01 群创光电股份有限公司 发光单元
CN116763752B (zh) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 一种阿卡波糖片剂及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JP2711528B2 (ja) * 1995-12-20 1998-02-10 大洋薬品工業株式会社 ロキソプロフェン製剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical Sulphonic derivatives, process for their preparation and their use
MXPA05004505A (es) 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
CN102134231B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP4919252B2 (ja) * 2004-08-05 2012-04-18 株式会社明治 顆粒状製剤及びその製造方法
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
PL1897558T3 (pl) * 2005-06-09 2014-01-31 Norgine Bv Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20080009530A1 (en) 2005-08-10 2008-01-10 Hidenori Abe Therapeutic Agent for Diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2007211005A (ja) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd 固形製剤用組成物および固形製剤
DK2248812T5 (da) 2006-06-27 2015-01-26 Takeda Pharmaceutical Kondenserede cykliske forbindelser som GPR40-receptormodulatorer
NZ575521A (en) 2006-09-13 2012-03-30 Takeda Pharmaceutical Use of 2-6-(3-amino-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
WO2008050821A1 (en) 2006-10-19 2008-05-02 Takeda Pharmaceutical Company Limited Indole compound
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
EP2124901B1 (en) * 2007-02-01 2017-07-19 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
EP2118066A1 (en) 2007-02-09 2009-11-18 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
AR065698A1 (es) * 2007-03-13 2009-06-24 Takeda Pharmaceutical Preparacion solida
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
US8400391B2 (en) 2008-01-10 2013-03-19 Honeywell International Inc. Method and system for improving dimming performance in a field sequential color display device

Also Published As

Publication number Publication date
CN102548556A (zh) 2012-07-04
US20120129878A1 (en) 2012-05-24
EP2460523B1 (en) 2017-01-04
CO6612226A2 (es) 2013-02-01
CL2012000182A1 (es) 2012-10-12
MA33539B1 (fr) 2012-08-01
PE20120919A1 (es) 2012-08-13
JP5732394B2 (ja) 2015-06-10
KR20120039046A (ko) 2012-04-24
TW201106991A (en) 2011-03-01
ZA201200761B (en) 2013-05-29
TN2012000031A1 (en) 2013-09-19
EA201270204A1 (ru) 2012-08-30
ECSP12011699A (es) 2012-03-30
JPWO2011013639A1 (ja) 2013-01-07
CA2769177A1 (en) 2011-02-03
CR20120061A (es) 2012-03-06
EP2460523A4 (en) 2014-02-26
BR112012001959A2 (pt) 2016-03-15
AU2010279171A1 (en) 2012-03-01
SG178062A1 (en) 2012-03-29
WO2011013639A1 (ja) 2011-02-03
IL217560A0 (en) 2012-02-29
EP2460523A1 (en) 2012-06-06
IN2012DN00954A (es) 2015-04-10

Similar Documents

Publication Publication Date Title
MX2012001284A (es) Tableta.
MX2009009703A (es) Preparacion solida que comprende 2-[[6-[(3r)-3-amino-1-piperidinil ]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-4-fluoro benzonitrilo.
TW200801000A (en) Spiroindolinone derivatives
TW200716107A (en) Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
MY183312A (en) Pharmaceutical formulation
PH12012502568A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
MY164646A (en) Nicotine lozenge compositions
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX2013001677A (es) Formulaciones estables de linaclotida.
MX2011012739A (es) Derivados fluorados de aminotriazol.
MX2011010415A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
TW200942530A (en) Pyridine compounds
MY155938A (en) Oral pharmaceutical composition
MX2011010359A (es) Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
TN2012000105A1 (en) Spirolactam derivatives and uses of same
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
MX2012002209A (es) Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.
WO2012064306A3 (en) Effervescent formulations of rosuvastatin
WO2010093889A3 (en) Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
WO2011014008A3 (ko) 신규 3-페녹시-4-파이론, 3-페녹시-4-피리돈 또는 4-피리돈 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 항균 조성물
UA38601U (en) 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity

Legal Events

Date Code Title Description
FA Abandonment or withdrawal